Most prominent among the regulators disrupted in cancer cells are two tumor suppressors, the retinoblastoma protein (RB) and the p53 transcription factor. Here, we discuss interconnecting signaling pathways controlled by RB and p53, attempting to explain their potentially universal involvement in the ...
the rb and p53 pathways in cancer:在癌rb和p53途径 下载积分:2000 内容提示: R E V I E WCANCER CELL : AUGUST 2002 · VOL. 2 · COPYRIGHT © 2002 CELL PRESS 103The RB and p53 pathways in cancerCharles J. Sherr 1,3 and Frank McCormick 21 Howard Hughes Medical Institute, St. Jude ...
Cancer cell cycles. Science 274, 1672–1677 (1996). Article PubMed CAS Google Scholar Sherr, C. J. & McCormick, F. The RB and p53 pathways in cancer. Cancer Cell 2, 103–112 (2002). Article PubMed CAS Google Scholar Hanahan, D. & Weinberg, R. A. The hallmarks of cancer. ...
in cancer, occurring in more than 50% of all human tumors, implying that loss of this gene represents a fundamentally important step in the pathogenesis of cancer.The pathway involving p53 may provide a common basis for understanding, treating, and preventing cancer.Using the method of ...
p53 mutation remains the most common genetic change identified in human neoplasia. In breast cancer, p53 mutation is associated with more aggressive disease and worse overall survival. The frequency of mutation in p53 is, however, lower in breast cancer
and I enumerated what we imagined were shared commonalities that unite all types of cancer cells at the level of cellular phenotype. The intent was to provide a conceptual scaffold that would make it possible to rationalize the complex phenotypes of diverse human tumor types and variants in terms...
RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011;10:1563e70.Jiang Z, Jones R, Liu JC, Deng T, Robinson T, Chung PE, Wang S, et al. RB1 and p53 at the crossroad of EMT and triple-negative breast cancer. Cell Cycle 2011;10:1563-1570....
Cancer stem cells (CSCs) are a high profile drug target for cancer therapeutics due to their indispensable role in cancer progression, maintenance and therapeutic resistance. Restoring wild-type (WT) p53 function is an attractive new therapeutic approach for the treatment of cancer due to the well...
Rb: retinoblastoma gene SOD-1: superoxide dismutase-1 TUNEL: terminal deoxynucleotidyl transferase-mediated biotin dUTP nick end-labeling References Greenblatt MS, Bennett WP, Hollstein M and Harris CC . 1994 Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathoge...
p53: 800 million years of evolution and 40 years of discovery Article 13 May 2020 Targeting p53 pathways: mechanisms, structures and advances in therapy Article Open access 01 March 2023 References Evan, G. I. & Vousden, K. H. Proliferation, cell cycle and apoptosis in cancer. Nature...